Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at firstname.lastname@example.org
Role of Gut Microbiome, Alpha Synuclein in the Prodromal Stage of Parkinson Disease
Virginia Gao, MD, PhD, a movement disorders fellow at Weill Cornell Medicine, discussed several topics related to the use of biomarkers in the prodromal stages of neurodegenerative disorders like Parkinson disease.
Poststroke Seizures Linked With Increased Mortality, Disability, Dementia
In the largest meta-analysis of patients with poststroke seizures, findings showed that those with early seizures had a greater mortality risk than those with late.
PathMaker Announces First-In-Human Trial of Neurostimulation Device MyoRegulator in ALS
In the study, patients with ALS will be asked to complete questionnaires, a physical examination, and undergo neurostimulation site visits 3 times per week for 4 weeks.
Episode 98: Uncovering Phenotypical Features of Narcolepsy Type 1
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Birgitte Kornum, MD. [LISTEN TIME: 18 minutes]
Phase 3 RESILIENT Study of SMA Agent Taldefgrobep Alfa Completes Enrollment
The double-blind trial will feature 180 patients of various spinal muscular atrophy types who will be followed over a 48-week treatment period.
NeuroVoices: Ruth Schneider, MD, on Addressing Psychosis in Lewy Body Diseases
The associate professor in the department of neurology at the University of Rochester provided insight on her presentation on psychosis in Parkinson disease and related disorders given at the 2023 ANA Annual Meeting.
FDA Approves AI-Incorporated Alzheimer Detection Software AIRAscore
The AIRAscore may help optimize the diagnostic process of neurodegenerative disorders by comparing brain structures with collected age- and gender-specific qualitative data samples.
FDA Updates Label for Psychosis Medication Pimavanserin
Approved in 2016, the newly updated label changes add more clarity to the use of pimavanserin, noting that patients with Parkinson disease with dementia may be eligible for treatment.
Visual Hypersensitivity Positively Associated With Patient Outcomes in CGRP-Treated Individuals With Migraine
Visual hypersensitivity decreased after 3 months of treatment, with a clear association with clinical response to treatment regarding migraine days.
Building a Greater Understanding of Ulixacaltimide’s Impact in Essential Tremor
Marcio Souza, president and chief executive officer at Praxis Precision Medicines provided follow-up thoughts on recently announced positive findings assessing ulixacaltamide in patients with essential tremor.
Rebound Relapse Effect Identified in NMOSD Following Eculizumab Discontinuation
In this small-scale Turkish-based substudy, stopping eciluzumab appeared to be associated with a “rebound” effect with a high risk of relapse in patients with NMOSD.
Alzheimer Agent ALZ-801 Improves Cognition, Reduces Relevant Biomarker Levels in 2-Year Analysis
Over a 2-year treatment period, patients on ALZ-801 demonstrated significant correlations between effects on volumetric MRI outcomes and 3 cognitive scales, suggesting cognitive gains are a result of preservation of brain structures from neurodegeneration and atrophy.
Super-Refractory Status Epilepticus Linked With Unknown Etiologies, High Mortality Rates
Patients treated for more than 28 days had a higher chance of status epilepticus cessation, but also a high risk of moderate to severe disability at discharge.
Antiseizure Therapy Fenfluramine Continues to Show Pronounced Benefits in Rare, Developmental Epilepsies
One meta-analysis featuring 8 studies showed that more than half of patients reported a 100% reduction in their generalized tonic-clonic seizures or tonic-clonic seizures.
Nerivio Remote Electrical Neuromodulation Device Safe to Treat Migraine During Pregnancy
Treatment with Nerivio did not differ from controls in outcomes of newborn weight, miscarriage rate, preterm birth rate, birth defect rate, stillbirths, and rate of newborns meeting developmental milestones 3 months postnatal.
Despite Failing to Meet Primary End Point, AMO-02 Shows Additional Benefits in Myotonic Dystrophy
A composite analysis of motor skills, muscle strength, cognitive ability, daily living skills, and biomarker data showed statistically significant benefits with AMO-02.
Episode 97: Identifying Gaps in Access to Parkinson Disease Care
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Beck, PhD. [LISTEN TIME: 15 minutes]
Rapid Administration of Diazepam Results in Improved Seizure Cluster Cessation, Shorter Seizures
Treatment with diazepam nasal spray resulted in a statistically significant change in time between seizure clusters, potentially reflecting a beneficial effect of intermittent rescue therapy.
Early-Stage Findings of Ketogenic Agent CER-0001 in Infantile Spasms Warrant Further Investigation
Half of the treated individuals saw a reduction of more than 50% in the number and duration of epileptic spasms following treatment with CER-0001, a ketogenic therapy.
FDA Issues Ravulizumab Complete Response Letter for NMOSD, Citing Needed Changes to REMS Program
The agency requested modifications to the REMS program, seeking validation of patients’ meningococcal vaccination status and prophylactic administration of antibodies prior to giving ravulizumab treatment.
NeuroVoices: Sandeep Rana, MD, on Progress in Adult-Onset Spinal Muscular Atrophy
The director of the ALS Clinic at Allegheny Health Network provided perspective on the advancements in the treatment and management of adult-onset spinal muscular atrophy.
The Ever-Changing Management of Dyskinesia in Parkinson Disease
An expert panel discusses diagnosis and treatment of patients with Parkinson
disease, exploring the challenges in managing dyskinesia, finding a balance
between OFF episodes and ON time, and current and emerging treatment options.
Continuous Subcutaneous Apomorphine Infusion Demonstrates Durable Effect on OFF, ON Time in Parkinson Disease
More than a 40% improvement in ON time without troublesome dyskinesia occurred as patients had their treatment titrated.
Ethical Values and Principals in Neurology Departments, Medical School
A group of esteemed panelists discussed the important values neurology department directors and educators should prioritize when teaching students of the future. [WATCH TIME: 6 minutes]
Future Changes to Neurology Residency and Fellowship Programs
A trio of former and current neurology department directors discussed ways in which residency and fellowship programs may change as technology and therapeutic capabilities continue to expand. [WATCH TIME: 8 minutes]
Levodopa as Initial Parkinson Treatment Shows Best Long-Term Prognostic Outcome for Quality of Life
When compared with levodopa-sparing agents, treatment levodopa alone resulted in significantly better patient-rated Parkinson’s Disease Questionnaire activities of daily living and summary index scores.
Research Identifies Novel Genetic Risk Factor of Parkinson Disease in African Populations
Findings of a new novel genetic risk factor could inform future GBA1 clinical trials, improving patient stratification and the odds of designing trials that are more likely to produce meaningful and actionable answers.
Creating Efficient, Well-Rounded Neurology Departments
A panel of former AUPN presidents detailed how advances in neurology have changed the way the clinical specialty is taught, and why collaboration among leadership remains vital to creating an effective neurology department. [WATCH TIME: 7 minutes]
Inspiring a Young Generation of Neurologists
Former presidents of the AUPN shared perspective on the advances in neurology and how it was taught during their tenure.
IncobotulinumtoxinA Shows Long-Term Treatment Effect on Parkinson Disease Sialorrhea
Swallowing difficulties, a major concern for patients with Parkinson disease, occurred rarely in the study, and were spontaneously resolved over time.
2 Clarke Drive Cranbury, NJ 08512